Dr. Schlumbrecht on Treatment in Uterine Leiomyosarcoma

Partner | Cancer Centers | <b>Sylvester Comprehensive Cancer Center</b>

Matthew P. Schlumbrecht, MD, discusses the treatment of women with uterine leiomyosarcoma.

Matthew P. Schlumbrecht, MD, associate professor and co-director of Cancer Prevention and Control, Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the treatment of women with uterine leiomyosarcoma.

Eligible patients should undergo resection, says Schlumbrecht. Notably, adjuvant chemotherapy has not shown a benefit in women who undergo a complete resection.

For women with unresectable disease, single-agent doxorubicin or the combination of gemcitabine and docetaxel can be considered, says Schlumbrecht. As no data have emerged regarding the optimal sequencing of these therapies, treatment selection should be discussed with the patient.

Research efforts regarding targeted therapy in uterine leiomyosarcoma, as well as the development of clinical trials are important aspects that will help further progress in the field, concludes Schlumbrecht.